These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 34196018)

  • 1. Summary concordance index for meta-analysis of prognosis studies with a survival outcome.
    Hattori S; Zhou XH
    Stat Med; 2021 Oct; 40(24):5218-5236. PubMed ID: 34196018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of predictive capacities of biomarkers based on research synthesis.
    Hattori S; Zhou XH
    Stat Med; 2016 Nov; 35(25):4559-4572. PubMed ID: 27364316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time-dependent summary receiver operating characteristics for meta-analysis of prognostic studies.
    Hattori S; Zhou XH
    Stat Med; 2016 Nov; 35(26):4746-4763. PubMed ID: 27397119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trace elements as tumor biomarkers and prognostic factors in breast cancer: a study through energy dispersive x-ray fluorescence.
    Silva MP; Soave DF; Ribeiro-Silva A; Poletti ME
    BMC Res Notes; 2012 Jul; 5():194. PubMed ID: 22534013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sensitivity analysis for publication bias in meta-analysis of diagnostic studies for a continuous biomarker.
    Hattori S; Zhou XH
    Stat Med; 2018 Feb; 37(3):327-342. PubMed ID: 28990209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which one is a valuable surrogate for predicting survival between Tomita and Tokuhashi scores in patients with spinal metastases? A meta-analysis for diagnostic test accuracy and individual participant data analysis.
    Lee CH; Chung CK; Jahng TA; Kim KJ; Kim CH; Hyun SJ; Kim HJ; Jeon SR; Chang UK; Lee SH; Moon SH; Majeed H; Zhang D; Gravis G; Wibmer C; Kumar N; Moon KY; Park JH; Tabouret E; Fuentes S
    J Neurooncol; 2015 Jun; 123(2):267-75. PubMed ID: 25947287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of prognostic studies for a biomarker with a study-specific cutoff value.
    Sadashima E; Hattori S; Takahashi K
    Res Synth Methods; 2016 Dec; 7(4):402-419. PubMed ID: 26873370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
    Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
    Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
    Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
    Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A non-linear optimisation method to extract summary statistics from Kaplan-Meier survival plots using the published P value.
    Irvine AF; Waise S; Green EW; Stuart B
    BMC Med Res Methodol; 2020 Oct; 20(1):269. PubMed ID: 33126853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study.
    Stavridi F; Kalogeras KT; Pliarchopoulou K; Wirtz RM; Alexopoulou Z; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Koutras A; Lazaridis G; Christodoulou C; Pentheroudakis G; Laskarakis A; Arapantoni-Dadioti P; Batistatou A; Sotiropoulou M; Aravantinos G; Papakostas P; Kosmidis P; Pectasides D; Fountzilas G
    PLoS One; 2016; 11(10):e0164013. PubMed ID: 27695115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluate Cutpoints: Adaptable continuous data distribution system for determining survival in Kaplan-Meier estimator.
    Ogłuszka M; Orzechowska M; Jędroszka D; Witas P; Bednarek AK
    Comput Methods Programs Biomed; 2019 Aug; 177():133-139. PubMed ID: 31319941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. International Breast Cancer Study Group.
    Gelber RD; Goldhirsch A; Cole BF
    Control Clin Trials; 1993 Dec; 14(6):485-99. PubMed ID: 8119064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
    Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
    J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of the skeletal muscle index and systemic inflammatory index in patients with lymph node-positive breast cancer after radical mastectomy.
    Tang R; Deng JP; Zhang L; Zhang WW; Sun JY; Chi F; Zhang J; Wu SG; He ZY
    BMC Cancer; 2022 Mar; 22(1):234. PubMed ID: 35241010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of survival analysis methods for cancer gene expression RNA-Sequencing data.
    Raman P; Zimmerman S; Rathi KS; de Torrenté L; Sarmady M; Wu C; Leipzig J; Taylor DM; Tozeren A; Mar JC
    Cancer Genet; 2019 Jun; 235-236():1-12. PubMed ID: 31296308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative analysis of multiple cancer prognosis studies with gene expression measurements.
    Ma S; Huang J; Wei F; Xie Y; Fang K
    Stat Med; 2011 Dec; 30(28):3361-71. PubMed ID: 22105693
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta analysis of advanced cancer survival data using lognormal parametric fitting: a statistical method to identify effective treatment protocols.
    Qazi S; DuMez D; Uckun FM
    Curr Pharm Des; 2007; 13(15):1533-44. PubMed ID: 17504149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A literature-based approach to evaluate the predictive capacity of a marker using time-dependent summary receiver operating characteristics.
    Combescure C; Daures JP; Foucher Y
    Stat Methods Med Res; 2016 Apr; 25(2):674-85. PubMed ID: 23117409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant FAM64A mRNA expression is an independent predictor of poor survival in pancreatic cancer.
    Jiao Y; Fu Z; Li Y; Zhang W; Liu Y
    PLoS One; 2019; 14(1):e0211291. PubMed ID: 30695070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.